Market Research Logo

Global Influenza Vaccine Market: Industry Analysis & Outlook (2017-2021)

Global Influenza Vaccine Market: Industry Analysis & Outlook (2017-2021)

Influenza, also known as flu, is a contagious disease which spreads from person to person very rapidly. When an infected person sneezes or coughs the virus spreads to those close by, affecting immuno-compromised patients the most. The influenza virus is broadly classified as influenza A, influenza B, and influenza C. The influenza vaccine come in both inactive and weakened viral forms.

The global influenza vaccine market is relatively untouched and has huge potential to treat any major outbreak. The influenza vaccine market in the US is the largest market globally because of its strong dynamics and a great scope of innovation in the region. The growth factors of the market include increase in incidence of H1N1 outbreaks, rising spending on public healthcare programs, growth of the market in emerging economies, escalating ageing population and increase in spending on medicines and healthcare expenditure.

The global influenza vaccine market is trending with development of new drugs, use of new technologies, rise in FDA approvals, and increase in efficiency rate of influenza vaccines, booming public private partnership and growing awareness. However, the market growth will be hindered by complex development and production process, unclear process for introduction of new vaccines and high R&D costs.

The report offers an in-depth analysis of the global influenza vaccine market along with regional insights. The top notch players in the market exhibit a very close competition. The report profiles Sanofi S.A, Novartis AG, AstraZeneca PLC and GlaxoSmithKline Plc.


1. Market Overview
1.1 Influenza
1.1.1 Types of Influenza
Table 1: Types of Influenza
Table A: Difference between Influenza Types A, B and C Viruses
1.1.2 Symptoms
Table 2: Symptoms of Influenza
1.2 Influenza Vaccine
1.2.1 Types
1.2.2 Supply Chain of Influenza Vaccine
Table 3: Supply Chain of Influenza Vaccine
1.2.3 Side Effects
Table B: Influenza Vaccine Side Effects
2. Global Influenza Vaccine Market Analysis
2.1 Global Influenza Vaccine Market by Value
Table 4: Global Influenza Vaccine Market by Value (2012-2016)
2.2 Global Influenza Vaccine Market Forecast by Value
Table 5: Global Influenza Vaccine Market Forecast by Value (2017-2021)
2.3 Global Influenza Vaccine Production Capacity by Indication
Table 6: Global Influenza Vaccine Production Capacity by Indication (2016)
2.4 Global Influenza Vaccine Production Capacity
2.4.1 Global Pandemic Influenza Vaccine Production Capacity
Table 7: Global Pandemic Influenza Vaccine Production Capacity (2012-2016)
2.4.2 Global Pandemic Influenza Vaccine Production Capacity Forecast
Table 8: Global Pandemic Influenza Vaccine Production Capacity Forecast (2017-2021)
2.4.3 Global Seasonal Influenza Vaccine Production Capacity
Table 9: Global Seasonal Influenza Vaccine Production Capacity (2012-2016)
2.4.4 Global Seasonal Influenza Vaccine Production Capacity Forecast
Table 10: Global Seasonal Influenza Vaccine Production Capacity Forecast (2017-2021)
2.5 Global Influenza Vaccine Market by Region
Table 11: Global Influenza Vaccine Market by Region (2016)
3. Regional Influenza Vaccine Market Analysis
3.1 The US
3.1.1 The US Influenza Vaccine Market by Value
Table 12: The US Influenza Vaccine Market by Value (2012-2016)
3.1.2 The US Influenza Vaccine Market Forecast by Value
Table 13: The US Influenza Vaccine Market Forecast by Value (2017-2021)
3.1.3 The US Influenza Vaccine Production Volume
Table 14: The US Influenza Vaccine Production Volume (2012-2016)
3.1.4 The US Influenza Vaccine Production Volume Forecast
Table 15: The US Influenza Vaccine Production Volume Forecast (2017-2021)
3.1.5 The US Influenza Vaccine Market Volume by Type
Table 16: The US Influenza Vaccine Market Volume by Type (2016)
3.2 Japan
3.2.1 Japan’s Influenza Vaccine Market by Value
Table17: Japan’s Influenza Vaccine Market by Value (2012-2016)
3.2.2 Japan’s Influenza Vaccine Market Forecast by Value
Table 18: Japan’s Influenza Vaccine Market Forecast by Value (2017-2021)
3.3 Germany
3.3.1 Germany’s Influenza Vaccine Market by Value
Table 19: Germany’s Influenza Vaccine Market by Value (2012-2016)
3.3.2 Germany’s Influenza Vaccine Market Forecast by Value
Table 20: Germany’s Influenza Vaccine Market Forecast by Value (2017-2021)
4. Market Dynamics
4.1 Key Trends & Developments
4.1.1 Increase in Development of New Drugs
4.1.2 Use of New Technology
4.1.3 Rise in FDA Approvals
Table C: Flu Vaccines Lots Released by the FDA (2016/2017)
4.1.4 Influenza Vaccine Effectiveness
Table 21: Vaccine Effectiveness for Influenza Seasons (2005-2016)
4.1.5 Booming Public-Private Corporation
4.1.6 Public Awareness on Rise
4.2 Growth Drivers
4.2.1 Development of H1N1/H5N1 Vaccines
Table D: H1N1/H5N1 Vaccine in Development (2015-2016)
4.2.2 Rise of Retail Clinics
Table E: Number of Retail Clinics in the US (2015)
4.2.3 Rising Spending on Public Health Programs
4.2.4 Growing Influenza Vaccine Market in Emerging Economies
4.2.5 Increased Spending on Medicines
Table 22: Global Spending on Medicines (2010-2020E)
Table 23: Total Spending on Medicines in the US (2012-2016)
4.2.6 Increasing Global Healthcare Expenditure
Table 24: Global Healthcare Expenditure (2012-2016)
4.2.7 Escalating Ageing Population
Table 25: Global Ageing Population of 60 Years or Older (2000-2030E)
4.3 Challenges & Issues
4.3.1 Complex Development and Production Process
4.3.2 Unclear Process in Introducing New Vaccines
4.3.3 High R&D Costs
5. Competitive Landscape
5.1 Global Influenza Vaccine Market
5.1.1 Market Share Comparison
Table 26: Global Influenza Vaccine Market Share (2016)
5.1.2 Competition by Drugs & Indication
Table F: Global Influenza Vaccine Market Competition by Drugs & Indication (2016)
5.1.3 Revenue Comparison
Table 27: Revenue Comparison by Key Players (2016)
5.1.4 Market Cap Comparison
Table 28: Market Cap Comparison by Key Players (2016)
5.2 The US Influenza Vaccine Market
5.2.1 Production Volume Share
Table 29: The US Influenza Vaccine Production Volume Share (2016)
6. Company Profiles
6.1 Novartis AG
6.1.1 Business Overview
Table 30: Novartis Revenue Share by Segments (2015)
6.1.2 Financial Overview
Table 31: Novartis AG’s Revenue and Net Income (2012-2015)
6.1.3 Business Strategies
6.2 Sanofi S.A
6.2.1 Business Overview
Table 32: Sanofi S.A Net Sales Share by Business Segments (2015)
6.2.2 Financial Overview
Table 33: Sanofi S.A Net Sales and Net Income (2012-2015)
6.2.3 Business Strategies
Table G: Sanofi S.A Key Product Enhancement Strategies (2015)
6.3 GlaxoSmithKline Plc.
6.3.1 Business Overview
Table 34: GlaxoSmithKline Plc. Net Sales Share by Segments (2015)
6.3.2 Financial Overview
Table 35: GlaxoSmithKline Plc. Net Sales and Operating Profit (2012-2015)
6.3.3 Business Strategies
Table H: GlaxoSmithKline Plc. Core R&D Expenditure Allocation (2015)
Table I: GSK Product Development Pipeline in Pharmaceutical and Vaccine Segment (2015)
6.4 AstraZeneca
6.4.1 Business Overview
Table 36: AstraZeneca Revenue by Segment (2015)
6.4.2 Financial Overview
Table 37: AstraZeneca’s Revenue (2012-2015)
6.4.3 Business Strategies
Table J: AstraZeneca’s Approvals and Upcoming Drugs (2015)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report